Pharming Group NV (PHAR NASDAQ) stock market data APIs
$14.7381
0.31(2.1%)
as of September 12, 2025
Try our APIs with
free plan!
Pharming Group NV Financial Data Overview
Price chart is built with
Anychart
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Prev. Close
14.7381
Open
15.0439
High
15.0439
Low
14.1693
52 wk Range
7.31-17.08
Market Cap
1 006 M
Shares Outstanding
68 515 K
Revenue
340 M
EPS
0.06
Beta
0.586
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharming Group NV data using free add-ons & libraries
Get Pharming Group NV Fundamental Data
Pharming Group NV Fundamental data includes:
- Net Revenue: 340 M
- EBITDA: 26 370 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: -0.0125
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharming Group NV News
New
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Shares of Rapport Therapeutics RAPP surged 61.6% in a week after the company reported positive top-line data from a mid-stage study of its lead candidate, RAP-219, in patients with drug-resistant foca...
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Travere Therapeutics TVTX announced that the FDA, following further review of the supplemental new drug application (sNDA) for Filspari (sparsentan) in focal segmental glomerulosclerosis ("FSGS"), has...
Pharming Group promoted to the Euronext AMX® index
Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX�...
Pharming Group promoted to the Euronext AMX® index
Pharming Group N.V. Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted fr...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
